13 June 2017
US pharma giant Pfizer (NYSE: PFE) is considering building another manufacturing plant in Russia during the next several years, which is expected to be located in the Tatarstan Republic, one of Russia’s richest and economically developed regions, reports The Pharma Letter’s local correspondent.
Outlines of the possible project have been discussed during the meeting between John Young, president of Pfizer Essential Health, and Rustam Minnikhanov, President of Tatarstan, which took place during the recent St Petersburg Economical Forum, one of the most important business events in Europe, which is held annually in St Petersburg during June.
Details of the planned project are currently not disclosed.
On May 30, Pfizer officially started building its first Russian plant in the Kaluga Vorsino technopark, which takes place in cooperation with its local partner NovaMedica.
The establishment of Kaluga production is very important to Russia as, according to the country’s Ministry of Health, about 30% of drugs, licenses for the manufacture of which will be transferred by Pfizer to NovaMedica, are currently not produced in Russia. Among these products are drugs for the treatment of severe bacterial and fungal infections, rheumatological and oncological diseases, as well drugs which are used in anesthesiology. Most of them are on the list of vital and essential drugs in Russia.Print
09 July 2020
08 July 2020
08 July 2020
07 July 2020